Skip to content

Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain

CompletedNot applicableNCT05001399
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Study Purpose: This study will explore the feasibility of administering Holographic Memory Resolution® (HMR) to adults who are experiencing chronic pain for 6 months or more.

Study details

Official title
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain
Conditions
  • Chronic Pain
  • Headache, Migraine
  • Stress Disorders, Post-Traumatic
Interventions
  • Behavioral: Holographic Memory Resolution® (HMR)
Sponsor
Billings Clinic
Collaborators
Healing Dimensions, ACC
Start date
2021-10-25
Primary completion
2022-06-29
Sex
All
Age range
from 18 Years
Results posted
No results posted in this snapshot
Countries
United States
Total sites listed
2

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patient age 18 years or older * Suffering from pain of 4 or greater intensity on a 0-10 scale with "0" being no pain and "10" being worst possible pain. * Pain symptoms will have been present for at least 6 months. Patients with chronic migraine headaches will be eligible if headaches occur at least every two months. * Associated symptoms could include anxiety, depression, or physical symptoms such as pain, migraines, or other symptoms that have interfered with quality of life or work/life balance. * Interested clients will have primary care provider agreement to participate in the study. Exclusion Criteria: * Diagnosis of psychosis or schizoaffective disorder, personality disorder, or suicidal ideation. * Clients taking mood altering substances and those that have a propensity toward altering delta, theta, alpha, and beta wave ranges will be excluded. These substances include but are not limited to Cannabis/Marijuana/ hashish/THC, PCP, phencyclidine, or Angel dust, Barbiturates, Benzodiazepines, Opioids/heroin, Clozapine (+++delta/slow waves/- - alpha waves), Lithium, Stimulants/ (Illicit: Cocaine, Methamphetamine), and Hallucinogens/MDMA (ecstasy)/LSD. * Clients who ingest alcohol must be 3 months abstinent/in recovery before session if alcohol dependent and 48 hours abstinent before session if not alcohol dependent/in recovery.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05001399